Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAsopressin and STeroids in addition to Adrenaline in cardiac arrest
2019-002310-39Phase 3Active
- Sponsor
- TioHundra
- Start
- Jul 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of epinephrine and vasopressin in cardiac arrest (SCA) (2 arms), sponsored by TioHundra. Primary endpoint: Survival at 30 days. Started Jul 2019; status: active.
02
Drugs
epinephrinevasopressin
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on 2019-002310-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002310-39.